Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock Has Consensus Price Target of $16.20 According to Brokerages

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) has been given an average rating of “Moderate Buy” by the six research firms that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $17.00.

A number of equities research analysts recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xeris Biopharma in a report on Wednesday, November 4th. Leerink Partners increased their target price on Xeris Biopharma from $12.00 to $16.00 and gave the company an “outperform” rating in a research note on Thursday, September 10th. HC Wainwright raised their target price on Xeris Biopharma from $10.00 to $18.00 and gave the stock a “buy” rating in a report on Friday, November 6th. Barclays boosted their target price on Xeris Biopharma from $14.00 to $18.00 and gave the stock an “overweight” rating in a research report on Wednesday. Finally, Wall Street Zen raised Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 7th.

Insider Buying and Selling

In related news, insider Steven Pieper sold 5,000 shares of Xeris Biopharma stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $10.23, for a total transaction of $51,150.00. Following the transaction, the insider owned 1,346,053 shares of the company’s stock, valued at $13,770,122.19. This trade represents a 0.37% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin McCulloch sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, November 5th. The shares were sold at an average price of $12.49, for a total transaction of $312,250.00. Following the transaction, the insider owned 1,559,208 shares of the company’s stock, valued at approximately $19,474,507.92. This represents a 1.58% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 168,332 shares of company stock valued at $1,678,971 in the last 90 days. 4.35% of the stock is owned by insiders.

Hedge Funds Weigh In On Xeris Biopharma

Several institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. bought a new stake in shares of Xeris Biopharma in the 2nd quarter valued at $115,042,000. Wellington Management Group LLP lifted its holdings in Xeris Biopharma by 8.9% during the second quarter. Wellington Management Group LLP now owns 2,365,103 shares of the company’s stock worth $18,732,000 after acquiring an additional 193,749 shares in the last quarter. Legal & General Group Plc bought a new position in Xeris Biopharma during the second quarter worth about $15,941,000. Parkman Healthcare Partners LLC acquired a new position in Xeris Biopharma in the second quarter valued at about $14,316,000. Finally, Algert Global LLC grew its stake in Xeris Biopharma by 50.6% in the second quarter. Algert Global LLC now owns 1,742,942 shares of the company’s stock valued at $13,804,000 after acquiring an additional 585,984 shares during the period. Institutional investors and hedge funds own 42.75% of the company’s stock.

Xeris Biopharma Price Performance

XERS opened at $16.65 on Tuesday. The company has a fifty day moving average price of $10.24 and a two-hundred day moving average price of $7.79. The company has a debt-to-equity ratio of 3.89, a quick ratio of 1.02 and a current ratio of 2.15. Xeris Biopharma has a 52 week low of $5.25 and a 52 week high of $16.88. The firm has a market capitalization of $3.04 billion, a PE ratio of -332.93 and a beta of 0.61.

Xeris Biopharma (NASDAQ:XERS) last issued its earnings results on Thursday, November 5th. The company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.03 by $0.03. Xeris Biopharma had a negative net margin of 1.76% and a positive return on equity of 147.75%. The company had revenue of $107.23 million during the quarter, compared to analysts’ expectations of $101.68 million. As a group, analysts anticipate that Xeris Biopharma will post 0.15 earnings per share for the current year.

About Xeris Biopharma

Xeris Biopharma is a commercial-stage biopharmaceutical company focused on developing and providing treatments for people with endocrine and other serious health conditions. Its products include Gvoke, a ready-to-use glucagon product for the treatment of severe hypoglycemia, and Recorlev, a treatment for adults with endogenous hypercortisolemia associated with Cushing syndrome when surgery is not an option or has not been curative. The company also develops drug-delivery technologies intended to make medicines easier to store and administer.